AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. IONQ
2. IONS
3. AZN
4. SPY
5. NVDA
6. ROIV
7. CRCL
8. V
9. HOOD
10. XOM

Go back to AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection
AbbVie (NYSE: ABBV) Delayed: 252.66 -3.8 (1.48%)
Previous Close $256.46    52 Week High $68.12 
Open $251.84    52 Week Low $50.71 
Day High $252.66    P/E 54.81 
Day Low $248.86    EPS $4.61 
Volume 689,835